Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Cepheid group purchasing contract with Broadlane for molecular diagnostic tests

Cepheid : 30 November, 2007  (New Product)
Cepheid has signed a group purchasing contract with Broadlane that will enable Broadlane customers to take advantage of Cepheid's molecular diagnostic instruments, reagents and services for its GeneXpert System and Xpert line of tests, including Xpert MRSA.
Broadlane is a leading supply chain services company serving more than 20,000 acute care hospitals, ambulatory care facilities, physicians practices and other healthcare providers throughout the USA.

'This agreement with Broadlane expands access to the GeneXpert System, enabling rapid on-demand molecular diagnostics for thousands of healthcare providers large and small,' said Rob Koska, Cepheid's senior vice president of worldwide commercial operations.

'Broadlane counts among its clients more than 915 acute care hospitals, 2,600 sub-acute care facilities and more than 18,000 physician practices. Cepheid is making it both technically and economically possible to perform molecular diagnostics any time and anywhere, representing a major advancement as institutions seek new ways to reduce costly and deadly Healthcare Acquired Infection (HAI) rates.'

Cepheid currently markets Xpert MRSA, a molecular test that runs on the GeneXpert System for the rapid detection of Methicillin-resistant Staphylococcus aureus (MRSA). Xpert MRSA results, delivered in just over one hour, enable health professionals to rapidly identify carriers of the potential pathogen and allow healthcare organizations to implement the proper Infection control measures, leading to lower healthcare acquired infection rates while improving patient care.

In addition to Xpert MRSA, Cepheid currently markets Xpert EV for Enteroviral meningitis and Xpert GBS for Group B streptococcus in the USA.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo